Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

14.1K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
14.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical missense variant E282K in PPP3CA/calcineurin shifts substrate dephosphorylation by altering active site recruitment.

Nature communications·2026
Same author

Peptidoglycan recruitment by a penicillin binding protein.

Nature communications·2025
Same author

Cryo-EM structures of PP2A:B55 with p107 and Eya3 define substrate recruitment.

Nature structural & molecular biology·2025
Same author

Cryo-EM structures of PP2A:B55-FAM122A and PP2A:B55-ARPP19.

Nature·2023
Same author

Molecular basis of β-lactam antibiotic resistance of ESKAPE bacterium E. faecium Penicillin Binding Protein PBP5.

Nature communications·2023
Same author

Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction.

Nature communications·2023

Related Experiment Video

Updated: May 3, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.9K

NMR Based SARS-CoV-2 Antibody Screening.

Marta V Schoenle1, Yang Li2, Meng Yuan3

  • 1Biochemistry Graduate Program, University of Arizona, Tucson, Arizona 85721, United States.

Journal of the American Chemical Society
|May 21, 2021
PubMed
Summary

Understanding how antibodies target SARS-CoV-2 is key to fighting COVID-19. This study uses NMR spectroscopy to rapidly map antibody binding sites on the viral spike protein, aiding vaccine and therapy development.

More Related Videos

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.3K
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
08:21

Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

Published on: May 23, 2025

620

Related Experiment Videos

Last Updated: May 3, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.9K
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.3K
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
08:21

Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

Published on: May 23, 2025

620

Area of Science:

  • Biochemistry
  • Immunology
  • Structural Biology

Background:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters cells via its spike protein binding to the ACE2 receptor.
  • Antibodies (Abs) targeting the spike protein's receptor binding domain (RBD) are crucial for long-term immunity and blocking infection.

Purpose of the Study:

  • To achieve a comprehensive molecular understanding of how human antibodies recognize the SARS-CoV-2 RBD.
  • To accelerate the development of improved vaccines and COVID-19 antibody-based therapies.

Main Methods:

  • Sequence-specific backbone assignment of the SARS-CoV-2 RBD.
  • Biomolecular NMR spectroscopy chemical shift perturbation (CSP) mapping to identify molecular epitopes.
  • Integration of NMR data with other molecular techniques and neutralization efficacy.

Main Results:

  • Successfully assigned the backbone of the SARS-CoV-2 RBD.
  • Demonstrated rapid and successful identification of molecular epitopes for RBD-specific monoclonal antibodies (mAbs) using CSP mapping.
  • Established a correlation between RBD-mAb interactions and neutralization efficacy.

Conclusions:

  • NMR-based CSP mapping is an effective method for rapidly identifying antibody binding sites on the SARS-CoV-2 RBD.
  • Integrating NMR data with other techniques accelerates structure-based development of vaccines and antibody therapies for COVID-19.